Adult T-cell leukemia-lymphoma

Current treatment strategies and novel immunological approaches

Ryuji Tanosaki, Kensei Tobinai

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Adult T-cell leukemia-lymphoma (ATL) is a peripheral T-cell malignancy, closely associated with human T-cell lymphotropic virus type I infection. Clinically, ATL is classified into four subtypes: acute, lymphoma, chronic and smoldering type. Although the prognosis of chronic and smoldering-type ATL is relatively good, that of patients with acute- or lymphoma-type ATL still remains extremely poor. Zidovudine/IFN-α therapy seems to be promising, although its efficacy has not yet been confirmed in well-designed prospective studies. High-dose chemotherapy with the support of autologous transplantation does not improve outcome. Allogeneic stem cell transplantation is promising and approximately 40% of aggressive ATL patients are expected to survive long-term, although transplantation-related mortality is as high as 40-50%. Stem cell transplantation using reduced-intensity conditioning is also effective and safer, with graft-versus-ATL and graft-versus-human T-cell lymphotropic virus type I effects observed after transplantation. Novel approaches including new agents such as purine nucleoside phosphorylase inhibitors and histone deacetylase inhibitors, or targeted immunotherapy using antichemokine receptor-4 antibody or dendritic cell/peptide vaccine are also warranted.

Original languageEnglish
Pages (from-to)743-753
Number of pages11
JournalExpert Review of Hematology
Volume3
Issue number6
DOIs
Publication statusPublished - 2010 Dec
Externally publishedYes

Fingerprint

Adult T Cell Leukemia Lymphoma
Stem Cell Transplantation
T-Lymphocytes
Lymphoma
Therapeutics
Transplantation
Purine-Nucleoside Phosphorylase
Transplants
Subunit Vaccines
Histone Deacetylase Inhibitors
Zidovudine
Autologous Transplantation
Virus Diseases
Immunotherapy
Dendritic Cells
Prospective Studies
Viruses
Drug Therapy
Mortality
Antibodies

Keywords

  • adult T-cell leukemia-lymphoma
  • graft-versus-ATL effects
  • graft-versus-HTLV-1 effects
  • hematopoietic stem cell transplantation
  • human T-cell lymphotropic virus type I
  • IFN-α
  • reduced-intensity stem cell transplantation
  • treatment
  • zidovudine

ASJC Scopus subject areas

  • Hematology

Cite this

Adult T-cell leukemia-lymphoma : Current treatment strategies and novel immunological approaches. / Tanosaki, Ryuji; Tobinai, Kensei.

In: Expert Review of Hematology, Vol. 3, No. 6, 12.2010, p. 743-753.

Research output: Contribution to journalReview article

@article{7e9e17dacc63483eb6e4196308188692,
title = "Adult T-cell leukemia-lymphoma: Current treatment strategies and novel immunological approaches",
abstract = "Adult T-cell leukemia-lymphoma (ATL) is a peripheral T-cell malignancy, closely associated with human T-cell lymphotropic virus type I infection. Clinically, ATL is classified into four subtypes: acute, lymphoma, chronic and smoldering type. Although the prognosis of chronic and smoldering-type ATL is relatively good, that of patients with acute- or lymphoma-type ATL still remains extremely poor. Zidovudine/IFN-α therapy seems to be promising, although its efficacy has not yet been confirmed in well-designed prospective studies. High-dose chemotherapy with the support of autologous transplantation does not improve outcome. Allogeneic stem cell transplantation is promising and approximately 40{\%} of aggressive ATL patients are expected to survive long-term, although transplantation-related mortality is as high as 40-50{\%}. Stem cell transplantation using reduced-intensity conditioning is also effective and safer, with graft-versus-ATL and graft-versus-human T-cell lymphotropic virus type I effects observed after transplantation. Novel approaches including new agents such as purine nucleoside phosphorylase inhibitors and histone deacetylase inhibitors, or targeted immunotherapy using antichemokine receptor-4 antibody or dendritic cell/peptide vaccine are also warranted.",
keywords = "adult T-cell leukemia-lymphoma, graft-versus-ATL effects, graft-versus-HTLV-1 effects, hematopoietic stem cell transplantation, human T-cell lymphotropic virus type I, IFN-α, reduced-intensity stem cell transplantation, treatment, zidovudine",
author = "Ryuji Tanosaki and Kensei Tobinai",
year = "2010",
month = "12",
doi = "10.1586/ehm.10.73",
language = "English",
volume = "3",
pages = "743--753",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Adult T-cell leukemia-lymphoma

T2 - Current treatment strategies and novel immunological approaches

AU - Tanosaki, Ryuji

AU - Tobinai, Kensei

PY - 2010/12

Y1 - 2010/12

N2 - Adult T-cell leukemia-lymphoma (ATL) is a peripheral T-cell malignancy, closely associated with human T-cell lymphotropic virus type I infection. Clinically, ATL is classified into four subtypes: acute, lymphoma, chronic and smoldering type. Although the prognosis of chronic and smoldering-type ATL is relatively good, that of patients with acute- or lymphoma-type ATL still remains extremely poor. Zidovudine/IFN-α therapy seems to be promising, although its efficacy has not yet been confirmed in well-designed prospective studies. High-dose chemotherapy with the support of autologous transplantation does not improve outcome. Allogeneic stem cell transplantation is promising and approximately 40% of aggressive ATL patients are expected to survive long-term, although transplantation-related mortality is as high as 40-50%. Stem cell transplantation using reduced-intensity conditioning is also effective and safer, with graft-versus-ATL and graft-versus-human T-cell lymphotropic virus type I effects observed after transplantation. Novel approaches including new agents such as purine nucleoside phosphorylase inhibitors and histone deacetylase inhibitors, or targeted immunotherapy using antichemokine receptor-4 antibody or dendritic cell/peptide vaccine are also warranted.

AB - Adult T-cell leukemia-lymphoma (ATL) is a peripheral T-cell malignancy, closely associated with human T-cell lymphotropic virus type I infection. Clinically, ATL is classified into four subtypes: acute, lymphoma, chronic and smoldering type. Although the prognosis of chronic and smoldering-type ATL is relatively good, that of patients with acute- or lymphoma-type ATL still remains extremely poor. Zidovudine/IFN-α therapy seems to be promising, although its efficacy has not yet been confirmed in well-designed prospective studies. High-dose chemotherapy with the support of autologous transplantation does not improve outcome. Allogeneic stem cell transplantation is promising and approximately 40% of aggressive ATL patients are expected to survive long-term, although transplantation-related mortality is as high as 40-50%. Stem cell transplantation using reduced-intensity conditioning is also effective and safer, with graft-versus-ATL and graft-versus-human T-cell lymphotropic virus type I effects observed after transplantation. Novel approaches including new agents such as purine nucleoside phosphorylase inhibitors and histone deacetylase inhibitors, or targeted immunotherapy using antichemokine receptor-4 antibody or dendritic cell/peptide vaccine are also warranted.

KW - adult T-cell leukemia-lymphoma

KW - graft-versus-ATL effects

KW - graft-versus-HTLV-1 effects

KW - hematopoietic stem cell transplantation

KW - human T-cell lymphotropic virus type I

KW - IFN-α

KW - reduced-intensity stem cell transplantation

KW - treatment

KW - zidovudine

UR - http://www.scopus.com/inward/record.url?scp=78649510115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649510115&partnerID=8YFLogxK

U2 - 10.1586/ehm.10.73

DO - 10.1586/ehm.10.73

M3 - Review article

VL - 3

SP - 743

EP - 753

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 6

ER -